intranasal

Fluticasone furoate (Avamys) 是一种合成的三氟化皮质类固醇，衍生自氟替卡松，Kd 为 0.3 nM。Fluticasone furoate 具有有效的抗炎、抗哮喘活性和低全身暴露。Fluticasone furoate 可用作过敏性鼻炎治疗研究的鼻喷雾剂。

Vazegepant hydrochloride (Vazegepant HCl) 是一种用于偏头痛的鼻用 gepant，是一种高度亲和性CGRP 受体拮抗剂 (hCGRPKi=0.023 nM)。它可能有助于有效管理 COVID-19 相关肺部炎症。

Etripamil (MSP-2017) 是一种短效L 型钙通道拮抗剂，可用于治疗阵发性室上性心动过速的研究。它通过抑制房室结细胞中钙慢通道的钙离子流入，显示房室结传导并延长房室结不应期

GSK2245035 is a highly selective intranasal TLR7 agonist with preferential Type-1 interferon (IFN)-stimulating properties (pEC50s: 9.3 and 6.5 for IFNα and TFNα). It effectively suppresses allergen-induced Th2 cytokine production in human peripheral blood

Fpl 14294 is a novel CCK-8 agonist with effective intranasal anorectic activity in the rat.

Dexamethasone cipecilate is a long-acting intranasal corticosteroid and a highly lipophilic anti-inflammatory corticosteroid.

Cyclic di-IMP (sodium salt) (c-di-IMP) is a synthetic second messenger structurally related to the bacterial second messengers cyclic di-GMP and cyclic di-AMP . C-di-IMP has adjuvant properties when co-administered with antigens in vitro and by mucosal routes in vivo. C-di-IMP enriches the population of MHC class I and II, CD80, CD86, CD40, and CD54 positive dendritic cells derived from murine bone marrow. It also stimulates macrophages at 500 ng ml. Mice immunized with β-galactosidase (β-gal) plus c-di-IMP through the intranasal route show a humoral immune response, evidenced by an increase in IgG titers up to 2-fold compared to mice immunized with β-gal alone. Mice immunized with β-gal plus c-di-IMP also exhibit a Th1 Th2 response, indicating that the adjuvant activity of c-di-IMP leads to a cellular immune response as well.

Zanamivir-13C,15N2is intended for use as an internal standard for the quantification of zanamivir by GC- or LC-MS. Zanamivir is a sialic acid analog that inhibits neuraminidase release of newly replicated influenza virus particles.1It has been shown to selectively inhibit the growth of influenza A and B viruses in plaque reduction assays with IC50values ranging from 5 to 14 nM and to directly inhibit influenza A and B virus neuraminidases with IC50values ranging from 0.6 to 7.9 nMin vitro. Intranasal zanamivir administration at 0.4 mg kg twice daily reduces mortality and viral titers in lung homogenates of mice infected with influenza. 1.Elliott, M.Zanamivir: From drug design to the clinicPhilos. Trans. R. Soc. Lond. B Biol Sci.356(1416)1885-1893(2001)